RVV | A penny stock that may have an Influenza / Covid-19 treatment in its hands ?

Shares :


For several weeks, the world has been upside down due to the rapid spread of a virus to which no vaccine exists. The world’s largest pharmaceutical companies are working to find a cure as quickly as possible, and millions if not billions are on the table to make it happen.

“Millions and even billions of dollars will be spent to find a cure”

Revive Therapeutics | RVV released a news Friday that surprised the industry. Revive Therapeutics Explores the Use of Bucillamine as a Novel Treatment for Infectious Diseases including COVID-19

Revive Therapeutics is a company focused on the research, development and commercialization of novel psychedelic and cannabinoid-based life sciences products and drug repurposing for infectious diseases.

In addition, the company has just entered the psychedelic based product portfolio targeting multi-billion market opportunities market with the acquisition of Psilocin Pharma Corp.

According to Michael Frank, Revive’s Chief Executive Officer :

“Revive was founded on the premise of finding new uses for known drugs, and we are expanding on our rich product portfolio to target infectious diseases such as the coronavirus disease or COVID-19”

In recent years, the company has applied for a provisional patent with the US Patent and Trademark Office entitled “Use of Bucillamine in the Treatment of Infectious Diseases” (serial No. 62 / 991,996) and previously gone as far as conducting a Phase 2 study on the use of the drug for the purposes of treating acute gout flares, which was accepted by the FDA under an investigational new drug (IND) application.

With the latest developments, Revive Therapeutics Ltd. is exploring the use of the drug Bucillamine as a potential novel treatment for infectious diseases including influenza and the coronavirus disease (Covid-19).

Revive is developing a product and clinical development plan intending to unlock the full potential of Bucillamine :

From the Revive Therapeutics presentation

“Bucillamine (N- (mercapto-2-methylpropionyl) -l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine ​​derivative with two thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection “

The company which has just restructured with the arrival of the leader Michael Frank has only a market cap of $9 million despite the more than 10 patent filed in the psychedelic and Cannabis based patent portfolio.

What will happen with this potential new treatment ?

One thing is for sure, the potential of this drug is enormous and the intellectual property license may attract large pharmaceutical companies.

“Revive Therapeutics Ltd | RVV has a valuation of only around $9 million”

This new development can blow up the stock of Revive Therapeutics which is currently trading at only $8 cents. (at the time of publication)



This article is written and published by The Cannabis Stock

Disclaimer : The Cannabis Stock wants to promote the cannabis market with the best articles and news on the market. The Cannabis Stock does not recommend selling or buying any of the company mentioned and is not responsible for any losses that may result. The Cannabis Stock are engaged in the business of marketing and advertising companies

The Cannabis Stock and its employees may from time to time own shares of the companies named in the articles. All the facts reported by the cannabis stock are information that comes directly from the companies, from their website or on Sedar and are only published as information.

Disclosure : Revive Therapeutics Ltd is a paid clients of The Cannabis Stock.

Click on a star to rate this article !

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

Shares :